DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg is a corticosteroid indicated for the treatment of ocular inflammation and pain following ophthalmic surgery.

DEXTENZA is an ophthalmic insert that is inserted in the lower lacrimal punctum into the canaliculus. A single DEXTENZA insert releases a 0.4 mg dose of dexamethasone for up to 30 days following insertion.

What is DEXTENZA? DEXTENZA, a corticosteroid (or steroid) medicine, is used: To treat ocular (eye) inflammation (redness, swelling) and pain of the eye following eye surgery

DEXTENZA | Ordering and Reimbursement information to enable physician offices to locate and verify correct billing codes when prescribing DEXTENZA.

The most common ocular adverse reactions that occurred in patients treated with DEXTENZA were: anterior chamber inflammation including iritis and iridocyclitis (10%), intraocular pressure increased (6%), visual acuity reduced (2%), cystoid macular edema (1%), corneal edema (1%), eye pain (1%), and conjunctival hyperemia (1%).

The DEXTENZA Commercial Assurance Program is a patient assistance program designed to assist eligible* patients, who have coverage for DEXTENZA (J1096) through a commercial insurance plan .

Work with your DEXTENZA Field Reimbursement Manager to determine billable status for your payers and identify which plans allow for separate payment of drugs, new technologies, and pass-through drugs.

DEXTENZA is a corticosteroid indicated for the treatment of ocular inflammation and pain following ophthalmic surgery. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS DEXTENZA is contraindicated in patients with active corneal, conjunctival or canalicular infections, including epithelial herpes simplex keratitis (dendritic keratitis),

DEXTENZA, a corticosteroid (or steroid) medicine, is used: • To treat ocular (eye) inflammation (redness, swelling) and pain of the eye following eye surgery

Eligible patients may receive DEXTENZA at no cost: Provides free product for financially eligible uninsured, government insured, and commercially insured patients with no payer coverage for DEXTENZA. Program Eligibility Criteria US resident with a legal US mailing address.